Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine

NASDAQ: ACIU | July 2021

AC Immune

Disclaimer

This presentation contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

This presentation is strictly confidential, is being distributed to a limited range of invited persons solely for their own information, may not be distributed to the press or any other person, and may not be reproduced or published, in whole or in part, in any form.

SupraAntigen® and Morphomer® are registered trademarks of AC Immune SA in the following territories: AU, CH, EU, JP, and GB. Morphomer® is also a registered trademark of AC Immune SA in CN and NO.

Transformative acquisition accelerates time-to-market in Parkinson's[1]

Strategic pipeline expansion fully aligned with AC Immune's 3-pillar growth strategy



Strengthens pipeline with clinically validated a-syn[2] vaccine

- Lead candidate Affiris PD01 shows efficacy and safety in Phase 1
- Preparing an adaptive biomarker-based Phase 2 study in Parkinson's disease
- Additional preclinical vaccine programs targeting MSA[3] and DLB[4]

Strengthens balance sheet with acquisition & parallel financing

- Gross proceeds of $30M bolster strong cash position
- Company remains financed through at least Q1 2024[6]

Strengthens shareholder base by adding new industry leaders

- Athos Service GmbH[7], FCP[8] and MIG Fonds are lead investors in BioNTech
- Strong endorsement of Affiris PD01 and AC Immune's vaccine expertise

(1) Parkinson's disease; (2) Alpha-synuclein; (3) Multiple system atrophy; (4) Dementia with Lewy bodies; (5) Limbic-predominant age-related TDP-43 encephalopathy; (6) Not considering any incoming milestones; (7) Strüngmann family office; (8) First Capital Partner GmbH (Egger Family Office)

Vaccines have a unique position in the treatment and prevention of NDD[1]

Precision medicine maximizes pipeline potential



- Precision Medicine enables diagnosis of people at risk 10-20 years before symptoms occur, opening a completely new market segment of prevention of NDD
- Due to the long duration of action, vaccination will play an important role in long-term disease prevention and management
- The Covid-19 pandemic has demonstrated the safety and feasibility of a global vaccination approach and has significantly enhanced awareness and acceptability of vaccination

(1) Neurodegenerative diseases

Pathological oligomeric a-syn[1] is causally linked to PD[2] & other NDD[3]



- a-syn Misfolding and aggregation are the molecular basis for a-synucleinopathies, e.g. PD, DLB[4] and MSA[5]
- Molecular seeding and spreading is the potential driver of disease progression

(1) Alpha-synuclein; (2) Parkinson's disease; (3) Neurodegenerative diseases; (4) Dementia with Lewy bodies; (5) Multiple system atrophy

Anti-a-syn vaccine PD01 is clinically validated[1]

Phase 1 results support best-in-class profile

1. Safe and well tolerated with no safety concerns noted in patients followed for more than 3.5 years
2. Induced strong and boostable antibody responses
3. Evidence of target engagement: 50% reduction in pathological (oligomeric) a-syn[2] in the CSF[3]
4. Signal of clinical efficacy: stabilization of UPDRS III[4] scores correlated with reductions in oligomeric a-syn


THE LANCET
Neurology

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, Petra Lührs, Caroline Thun-Hohenstein, Achim Schneeberger, Gergana Galabova, Nour Majbour, Nishant Vaikath, Omar El-Agnaf, Dorian Winter, Eva Mihailovska, Andreas Mairhofer, Carsten Schwenke, Günther Staffler, Rossella Medori

(1) Volc *et al.*, Lancet Neurol. 2020; (2) Alpha-synuclein; (3) Cerebrospinal fluid; (4) Unified Parkinson's Disease Rating Scale

AC Immune moves to the forefront of Parkinson's[1] drug development

Complementary portfolio covers full spectrum of treatment modalities targeting a-syn[2]

Product candidates	Leading therapies and diagnostics:			
	vaccine	antibody	small molecule	diagnostic
				
Current focus[3]	PD[1]	PD	PD, NeuroOrphan	PD
Status	**Preparing adaptive Phase 2 study**	**Preclinical**	**Discovery**	**First-in-human study**

■ Clinical-stage vaccine significantly accelerates potential time-to-market in PD

(1) Parkinson's disease; (2) Alpha-synuclein; (3) Programs can be expanded into additional a-synucleinopathies

ACI-7104: Preparing for adaptive biomarker-based Phase 2 study

Key Inclusion Criteria: Early PD[1]	▪ Idiopathic PD[1] untreated or treated with MAO-B[2] inhibitor (stable for >3 months) ▪ A diagnosis of PD for 2 years or less at screening (not demented / no cognitive impairment) ▪ Dopaminergic deficit by DaT SPECT[3]

Key Design Features	▪ Seamless transition from Part 1 to Part 2
	  ▪ All participants from Part 1 will contribute to final analysis
	▪ Biomarker based interim analyses
	  ▪ Early immunogenicity to tailor dose and dosing schedule
	  ▪ Understand biological signal for early transition to filing

Part 1 Safety, Tolerability & Immunogenicity	▪ Key immunogenicity measures ▪ Measures of pathological a-syn[4] and a-syn aggregation, e.g. phospho-a-syn and a-syn-oligomers
Part 2 PoC[5] in Early PD	▪ Motor and Non-Motor Functioning (UPDRS[6] based) ▪ Neurodegeneration of dopaminergic terminals (DaT SPECT or VMAT2[7] imaging) ▪ Digital biomarkers of motor and non-motor function ▪ Advanced MRI (including ASL[8] and DTI[9]) ▪ Functional and patient reported outcomes

(1) Parkinson's disease; (2) Monoamine Oxidase Type B; (3) **D**op**a**mine **T**ransporter Single Photon Emission Computed Tomography; (4) Alpha-synuclein; (5) Proof-of-concept; (6) Unified Parkinson's disease rating scale; (7) Vesicular monoamine transporter 2; (8) Arterial spin labeling; (9) Diffusion tensor imaging

Leveraging AC Immune's unmatched development expertise

- A pioneer in neurodegeneration with a robust pipeline targeting Amyloid-beta, Tau, a-syn[1], and TDP-43, which have similar mechanisms of eliciting neurodegeneration with significant overlap
- Exclusive access to many years of invaluable cross learnings between approaches, technologies and competencies
- Successful clinical experience with anti-pTau and anti-Abeta vaccines will further enrich and accelerate development of the anti-a-syn vaccine

World-leading active vaccine pipeline in NDD[2]:

CANDIDATE	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
ACI-7104 *(anti-a-syn vaccine)*	PD[3], a-synucleinopathies					
ACI-35.030 *(anti-pTau vaccine)* Janssen	AD[4] treatment					
ACI-24 *(anti-Abeta vaccine)*	AD treatment (*Down syndrome[5]*)					
	AD treatment					

(1) Alpha-synuclein; (2) Neurodegenerative diseases; (3) Parkinson's disease; (4) Alzheimer's disease; (5) Down syndrome-related Alzheimer's disease

All-stock acquisition + PIPE[1] maintain and enhance strong cash position

Company operations remain fully funded based on current cash to at least Q1 2024[2]

1 MIG investment and a-syn assets acquisition

Anti-a-syn[3] therapeutic portfolio value	$53.7M
MIG Fonds investment into portfolio	$5M
Number of ACIU shares to Affiris[4]	7.1M
Price per share	$8.26

2 Private Placement (PIPE)

Athos (lead investor)[5]	$12.5M
First Capital Partner GmbH[6]	$12.5M
Number of shares to investors	3.0M
Price per share	$8.26

Anti-a-syn portfolio + $5 million

$25 million total gross proceeds

$30 million added to balance sheet

(1) Private investment in public equity; (2) Not considering any incoming milestones; (3) Alpha-synuclein; (4) Main shareholders of Affiris are Athos Service GmbH (Strüngmann family office); First Capital Partner GmbH (Egger Family Office) and MIG Fonds; (5) Strüngmann family office; (6) Egger Family Office

Transformative acquisition enhances ACIU's leadership in active vaccination

World-leading active vaccine pipeline in neurodegeneration

CANDIDATE	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
ACI-7104 *(anti-a-syn vaccine)*	PD[1], a-synucleinopathies					
ACI-35.030 *(anti-pTau vaccine)*	AD[2] treatment					
ACI-24 *(anti-Abeta vaccine)*	AD treatment (*Down syndrome[3]*)					
	AD treatment					

(1) Parkinson's disease; (2) Alzheimer's disease; (3) Down syndrome-related Alzheimer's disease



Questions & answers